{"release":{"schemaVersion":"maha-epistemic-release/1.0","releaseId":"epirelease_68c940c82a01459ba867852e5561a912","releaseKind":"initial","status":"active","recordId":"urn:maha:record:in-vitro-versus-in-vivo-evidence","domainSlug":"synthetic-biology","targetSha256":"sha256:04191ae798998644f3e9e348b443c465e6b6da590f5482685c2b1589eb248072","canonicalPath":"/knowledge/synthetic-biology/comparisons/in-vitro-versus-in-vivo-evidence","canonicalVersion":"1.0.0","supersedesReleaseId":null,"approvals":[{"scope":"boundary-adequacy","reviewId":"epireview_49166a4936df4aea9bc282c09f2d013a","reviewSha256":"sha256:7404da4c3a891e12c6c00e042efa61642d26b008c0472fe0653d7ce98024a0f7","reviewedAt":"2026-08-30T16:02:03.819Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"domain-fidelity","reviewId":"epireview_d6907cd107f54271947eda8d3ef04768","reviewSha256":"sha256:f5f268b389e9a6801b29b4daa929ca361a851822f2823bee6331a3ec0a8f2bba","reviewedAt":"2026-08-30T16:02:03.740Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"rights-and-locator","reviewId":"epireview_8ba9518d166a4b9aa7be0a03e7447e65","reviewSha256":"sha256:f59dd8440507ed973802dd58e39afc9d8fc16264b155149bc4238f1bc570c6f8","reviewedAt":"2026-08-30T16:02:03.897Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."},{"scope":"source-fidelity","reviewId":"epireview_bc866504140a4c07893ba90c0e8b115c","reviewSha256":"sha256:19dab9c25e2de9a56531e2da5ae0c9a8120eaffc2938ab285d7f9a6662b66645","reviewedAt":"2026-08-30T16:02:03.671Z","reviewerKind":"internal-editorial","reviewMethod":"Each criterion is recomputed from the exact record, its inspected alignment audit, source identity, exact locator, rights basis, claim scope, boundary, uncertainty, replication status, prohibited inferences, and revision digest."}],"assuranceTier":"internally-reviewed-canonical","releaseAuthority":{"authoritySha256":"sha256:2a0161a3927ae8366af44bda6671b5249802843ff3895dc292c90e5466b88609","attribution":"withheld-by-consent"},"publicChangeSummary":"Initial canonical publication under the disclosed exact-revision internal editorial tier.","recordSha256":"sha256:1f458c5ae7945d793266f1755a6dd204d3d1f1b4eb1e48624cc5be91bf142f0e","gateDecision":{"reasons":[],"recordId":"urn:maha:record:in-vitro-versus-in-vivo-evidence","publicEligible":true,"evaluatedAgainst":"maha-epistemic/1.0"},"releasedAt":"2026-08-30T16:02:56.529Z","releaseSha256":"sha256:9d95f48b5e1582fa46fedcf2f5fd03014ef4cb9a66debd1d0d4440cd1408f299","withdrawal":null},"provenance":{"schemaVersion":"maha-epistemic/1.0","evidencePolicyVersion":"mps/0.1","recordId":"urn:maha:record:in-vitro-versus-in-vivo-evidence","canonicalPath":"/knowledge/synthetic-biology/comparisons/in-vitro-versus-in-vivo-evidence","contentHash":"sha256:1f458c5ae7945d793266f1755a6dd204d3d1f1b4eb1e48624cc5be91bf142f0e","generatedAt":"2026-08-30T16:02:56.529Z","publicationDecision":{"recordId":"urn:maha:record:in-vitro-versus-in-vivo-evidence","publicEligible":true,"evaluatedAgainst":"maha-epistemic/1.0","reasons":[]},"claims":[{"id":"urn:maha:claim:in-vitro-versus-in-vivo-evidence","scope":"The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.","boundary":"In-vivo evidence is still intervention-, tissue-, dose-, population-, endpoint-, comparator-, and follow-up-specific and does not become universal.","claimKind":"empirical-claim","sourceIds":["source-gillmore-in-vivo-2021"],"statement":"The cited phase 1 study measures delivery-linked editing effects and early observations in human participants rather than inferring them from an in-vitro assay.","replication":{"asOfDate":"2026-08-24","assessment":"This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.","independentReplicationCount":null},"uncertainty":{"kind":"qualitative","statement":"There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices."},"evidenceMaturity":"single-study"}],"sources":[{"id":"source-gillmore-in-vivo-2021","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2107454","title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","rights":{"note":"Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.","basis":"citation-with-paraphrase","quotationUsed":false},"authors":["Julian D. Gillmore","Ed Gane","Julian Taubel","Jingzhu Kao","et al."],"boundary":"Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.","publisher":"The New England Journal of Medicine","establishes":"The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.","identifiers":[{"value":"10.1056/NEJMoa2107454","scheme":"doi"}],"publishedAt":"2021-06-26","exactLocator":"Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.","conflictsOfInterest":"The study was funded by Intellia Therapeutics and Regeneron Pharmaceuticals; author relationships are disclosed."}],"reviewEvents":[{"reviewId":"epireview_bc866504140a4c07893ba90c0e8b115c","scope":"source-fidelity","targetSha256":"sha256:04191ae798998644f3e9e348b443c465e6b6da590f5482685c2b1589eb248072","reviewedAt":"2026-08-30T16:02:03.671Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_d6907cd107f54271947eda8d3ef04768","scope":"domain-fidelity","targetSha256":"sha256:04191ae798998644f3e9e348b443c465e6b6da590f5482685c2b1589eb248072","reviewedAt":"2026-08-30T16:02:03.740Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_49166a4936df4aea9bc282c09f2d013a","scope":"boundary-adequacy","targetSha256":"sha256:04191ae798998644f3e9e348b443c465e6b6da590f5482685c2b1589eb248072","reviewedAt":"2026-08-30T16:02:03.819Z","verdict":"approve","supersedesReviewId":null},{"reviewId":"epireview_8ba9518d166a4b9aa7be0a03e7447e65","scope":"rights-and-locator","targetSha256":"sha256:04191ae798998644f3e9e348b443c465e6b6da590f5482685c2b1589eb248072","reviewedAt":"2026-08-30T16:02:03.897Z","verdict":"approve","supersedesReviewId":null}]},"privacyBoundary":"Operational actor fingerprints, bearer credentials, private reviewer profiles, affiliations, conflicts, and non-consented authority identity fields are excluded."}